Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05726253
Other study ID # 2023-5696
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date January 9, 2023
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source Ann & Robert H Lurie Children's Hospital of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

National guidelines make two recommendations for treatment of young children with mild pneumonia - one to avoid routine antibiotics and another to use narrow-spectrum antibiotics. No studies have compared the effectiveness of these two approaches. This pilot study will evaluate study processes and feasibility of a future clinical trial that proposes to test whether low-risk children managed as outpatients with mild community-acquired pneumonia (CAP) treated with supportive treatment without antibiotics will have a similar clinical response, with fewer adverse effects, compared with those treated with a supportive treatment plan that includes antibiotics.


Description:

This pilot clinical trial is a randomized, placebo-controlled, double-blinded trial assessing the feasibility of comparing supportive care+amoxicillin to supportive care without antibiotics (i.e., placebo) in children 12 months to <6 years of age who present to the ED with community-acquired pneumonia (CAP) and who will be treated as outpatients. This trial will enroll over a 6-month period and take place at Ann and Robert H. Lurie Children's Hospital of Chicago. Clinical research coordinators (CRCs) will screen for and enroll eligible children. Through an online system, participants will be randomized to a 7-day course of either amoxicillin (80-100 mg/kg divided BID up to 4,000 mg/day) or matching placebo. All patients will receive a supportive care treatment bundle that includes antipyretics, honey, and saline spray, in addition to instructions on how to manage lower respiratory infections. The guardians of participants will be asked to complete an online daily symptom diary during the first 6 days after the initial study visit. Participants will have daily telehealth evaluations by clinicians for the first three days after the index study visit. The primary outcome will be assessed at day 7, using telehealth technology. A final follow-up, performed by site research staff, by telephone call, will occur at Day 21 to assess overall disease course and secondary outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Months to 71 Months
Eligibility Inclusion Criteria: 1. Age 12-71 months; and 2. Diagnosis of CAP, defined using established criteria: 1. Signs and symptoms of lower respiratory tract infection (LRTI), defined as any of the following: - new or different cough; or - new or different sputum production; or - chest pain; or - dyspnea/shortness of breath; or - documented tachypnea; or - abnormal findings consistent with LRTI on physical examination (e.g., crackles/rales, rhonchi, wheezing) and 2. Fever, defined as tactile temperature at home or measured temperature =38ºC rectal, =37.7ºC oral, or =37.5ºC axillary, and 3. Clinician diagnosis of CAP, 3. Intention to treat as an outpatient after ED/primary care visit, and 4. Mild disease, defined as lack of respiratory distress per adapted Pediatric Infectious Diseases Society/Infectious Diseases Society of America criteria: none of the following: dyspnea, concerning retractions per treating clinician, grunting, nasal flaring, apnea, altered mental status, SpO2<93% in room air, or respiratory rate >50 breaths per minute for ages 12-24 months or respiratory rate > 40 breaths per minute if age>24 months. Exclusion Criteria: 1. Hospitalization within one-month preceding study visit; or 2. Incomplete immunization status (<2 doses of Hib and pneumococcal vaccines); or 3. Chronic complex medical conditions (chronic heart disease followed by cardiology, chronic lung disease (not including asthma), congenital airway or lung malformations, cystic fibrosis, tracheostomy tube, requiring positive-pressure ventilation, neuromuscular disorders affecting the lungs or chest wall); or 4. Conditions that compromise the immune system (HIV with CD4 count less than 400, primary immunodeficiency, asplenia, sickle cell disease, receipt of hematopoietic stem cell or solid organ transplant, cancer on active chemotherapy, immunosuppressive agents, daily corticosteroids for more than 7 consecutive days in past 14 days); or 5. Systemic antibiotic receipt (more than 1 dose) within the previous two weeks of CAP diagnosis; or 6. Radiographic findings of a consolidation of a concerning size or complexity in the view of the treating clinician; or 7. Radiographic findings of complicated pneumonia (pleural effusion larger than trace in size, empyema, [complex/septated collection] abscess, necrotic lung disease); or 8. Pneumonia known to be due to bacterial source at the time of enrollment, as documented by blood culture or PCR if available, or another clear source of bacterial infection requiring immediate antibiotics; or 9. Diagnosed with pneumonia in the previous month; or 10. Provider diagnosis of aspiration pneumonia; or 11. Severe (type 1) drug allergy to amoxicillin; or 12. Any other condition that in the judgement of investigators or the clinical team could affect safety of the subject; or 13. No access to a telephone or video technology for follow-up; or 14. Current enrollment in another clinical trial of an investigational agent; or 15. Previous enrollment in this trial; or 16. Parent/guardian non-English or non-Spanish speaking; or 17. Known allergy to milk and/or red dye.

Study Design


Intervention

Drug:
Supportive Care + Amoxicillin
Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
Supportive Care + Placebo (no antibiotics)
Participants will be randomized to receive oral placebo for a standard course (7 days)

Locations

Country Name City State
United States Ann & Robert H Lurie Children's Hospital of Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Ann & Robert H Lurie Children's Hospital of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Enrollment Rate Per Month Total number of participants enrolled divided by the total number of active enrollment months Measured at completion of pilot trial (6 months)
Secondary Consent Rate Number of eligible participants approached regarding trial participation who provided informed consent to participate in the trial compared with number of participants approached for participation Measured at completion of pilot trial (6 months)
Secondary Lost to Follow-Up at Day 7 Number of enrolled participants who did not complete the Day 7 follow-up visit Measured at completion of pilot trial (6 months)
Secondary Lost to Follow-Up at Day 21 Number of enrolled participants who did not complete the Day 21 follow-up visit Measured at completion of pilot trial (6 months)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01416506 - Community-Acquired Pneumonia (CAP) Surveillance N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A